Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Bright Futures Wealth Management LLC. cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 55.1% in the 4th ...

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price ...

Blue Trust Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 28.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson & Johnson Inc. has a lower P/E ratio ...

Johnson & Johnson (NYSE:JNJ) is a healthcare company engaged in the research, development, manufacturing, and marketing of a ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...